Do analysts rate ABVC or PBM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ABVC or PBM more profitable?

Psyence Biomedical's return on equity of 0.00% beat ABVC BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets ABVC BioPharma N/A -62.46% -39.99% Psyence Biomedical N/A N/A N/A

Does the media refer more to ABVC or PBM?

In the previous week, ABVC BioPharma and ABVC BioPharma both had 1 articles in the media. ABVC BioPharma's average media sentiment score of 0.00 equaled Psyence Biomedical'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ABVC BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Psyence Biomedical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer PBM or ALGS?

Aligos Therapeutics has a consensus price target of $38.50, indicating a potential upside of 704.09%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aligos Therapeutics is more favorable than Psyence Biomedical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aligos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86

Does the media favor PBM or ALGS?

In the previous week, Aligos Therapeutics had 3 more articles in the media than Psyence Biomedical. MarketBeat recorded 4 mentions for Aligos Therapeutics and 1 mentions for Psyence Biomedical. Aligos Therapeutics' average media sentiment score of 0.20 beat Psyence Biomedical's score of 0.00 indicating that Aligos Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Psyence Biomedical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aligos Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer PBM or ATNM?

Actinium Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 519.58%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than Psyence Biomedical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Actinium Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is PBM or ATNM more profitable?

Psyence Biomedical's return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Psyence Biomedical N/A N/A N/A Actinium Pharmaceuticals N/A -100.85% -47.89%

Do analysts prefer PBM or GRML?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Greenland Mines Ltd. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, PBM or GRML?

Greenland Mines Ltd. Common Stock is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Psyence Biomedical N/A N/A -$6.94M $25.34 0.13 Greenland Mines Ltd. Common Stock N/A N/A -$10.55M -$0.32 N/A

Is PBM or GRML more profitable?

Psyence Biomedical's return on equity of 0.00% beat Greenland Mines Ltd. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Psyence Biomedical N/A N/A N/A Greenland Mines Ltd. Common Stock N/A -109.40% -98.80%

Which has stronger valuation and earnings, ACTU or PBM?

Actuate Therapeutics is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Actuate Therapeutics N/A N/A -$22.23M -$0.97 N/A Psyence Biomedical N/A N/A -$6.94M $25.34 0.13

Is ACTU or PBM more profitable?

Psyence Biomedical's return on equity of 0.00% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Actuate Therapeutics N/A -430.93% -180.86% Psyence Biomedical N/A N/A N/A

Does the media refer more to ACTU or PBM?

In the previous week, Actuate Therapeutics had 1 more articles in the media than Psyence Biomedical. MarketBeat recorded 2 mentions for Actuate Therapeutics and 1 mentions for Psyence Biomedical. Actuate Therapeutics' average media sentiment score of 0.50 beat Psyence Biomedical's score of 0.00 indicating that Actuate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actuate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Psyence Biomedical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Psyence Biomedical (PBM) Competitors

$3.28 +0.13 (+4.13%)

As of 09:50 AM Eastern

Compare

PBM vs. ABVC, ALGS, ATNM, GRML, and ACTU

Should you buy Psyence Biomedical stock or one of its competitors? MarketBeat compares Psyence Biomedical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Psyence Biomedical include ABVC BioPharma (ABVC), Aligos Therapeutics (ALGS), Actinium Pharmaceuticals (ATNM), Greenland Mines Ltd. Common Stock (GRML), and Actuate Therapeutics (ACTU).

How does Psyence Biomedical compare to ABVC BioPharma?

ABVC BioPharma (NASDAQ:ABVC) and Psyence Biomedical (NASDAQ:PBM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

Psyence Biomedical's return on equity of 0.00% beat ABVC BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-62.46%	-39.99%
Psyence Biomedical	N/A	N/A	N/A

11.4% of ABVC BioPharma shares are owned by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are owned by institutional investors. 19.0% of ABVC BioPharma shares are owned by company insiders. Comparatively, 3.6% of Psyence Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Psyence Biomedical has lower revenue, but higher earnings than ABVC BioPharma. ABVC BioPharma is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	$510K	55.86	-$7.91M	-$0.40	N/A
Psyence Biomedical	N/A	N/A	-$6.94M	$25.34	0.13

ABVC BioPharma has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market. Comparatively, Psyence Biomedical has a beta of 1.66, suggesting that its share price is 66% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, ABVC BioPharma and ABVC BioPharma both had 1 articles in the media. ABVC BioPharma's average media sentiment score of 0.00 equaled Psyence Biomedical'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ABVC BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Psyence Biomedical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Psyence Biomedical beats ABVC BioPharma on 7 of the 9 factors compared between the two stocks.

How does Psyence Biomedical compare to Aligos Therapeutics?

Psyence Biomedical (NASDAQ:PBM) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

Psyence Biomedical has higher earnings, but lower revenue than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Psyence Biomedical	N/A	N/A	-$6.94M	$25.34	0.13
Aligos Therapeutics	$2.19M	13.53	-$24.19M	-$8.69	N/A

Psyence Biomedical has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Psyence Biomedical's return on equity of 0.00% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%

Aligos Therapeutics has a consensus price target of $38.50, indicating a potential upside of 704.09%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aligos Therapeutics is more favorable than Psyence Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Psyence Biomedical has a beta of 1.66, meaning that its stock price is 66% more volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.31, meaning that its stock price is 131% more volatile than the broader market.

77.4% of Psyence Biomedical shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 3.6% of Psyence Biomedical shares are held by insiders. Comparatively, 7.8% of Aligos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Aligos Therapeutics had 3 more articles in the media than Psyence Biomedical. MarketBeat recorded 4 mentions for Aligos Therapeutics and 1 mentions for Psyence Biomedical. Aligos Therapeutics' average media sentiment score of 0.20 beat Psyence Biomedical's score of 0.00 indicating that Aligos Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Psyence Biomedical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aligos Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Aligos Therapeutics beats Psyence Biomedical on 9 of the 16 factors compared between the two stocks.

How does Psyence Biomedical compare to Actinium Pharmaceuticals?

Psyence Biomedical (NASDAQ:PBM) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Psyence Biomedical has higher earnings, but lower revenue than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Psyence Biomedical	N/A	N/A	-$6.94M	$25.34	0.13
Actinium Pharmaceuticals	$90K	281.33	-$48.82M	-$0.75	N/A

In the previous week, Psyence Biomedical had 1 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 1 mentions for Psyence Biomedical and 0 mentions for Actinium Pharmaceuticals. Psyence Biomedical's average media sentiment score of 0.00 equaled Actinium Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Psyence Biomedical	Neutral
Actinium Pharmaceuticals	Neutral

Psyence Biomedical has a beta of 1.66, indicating that its share price is 66% more volatile than the broader market. Comparatively, Actinium Pharmaceuticals has a beta of -0.02, indicating that its share price is 102% less volatile than the broader market.

Actinium Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 519.58%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than Psyence Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

77.4% of Psyence Biomedical shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 3.6% of Psyence Biomedical shares are owned by company insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Psyence Biomedical's return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Summary

Psyence Biomedical beats Actinium Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Psyence Biomedical compare to Greenland Mines Ltd. Common Stock?

Psyence Biomedical (NASDAQ:PBM) and Greenland Mines Ltd. Common Stock (NASDAQ:GRML) are related small-cap companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

Psyence Biomedical has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market. Comparatively, Greenland Mines Ltd. Common Stock has a beta of 7.13, meaning that its share price is 613% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Greenland Mines Ltd. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

77.4% of Psyence Biomedical shares are held by institutional investors. Comparatively, 20.1% of Greenland Mines Ltd. Common Stock shares are held by institutional investors. 3.6% of Psyence Biomedical shares are held by company insiders. Comparatively, 11.3% of Greenland Mines Ltd. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Greenland Mines Ltd. Common Stock had 1 more articles in the media than Psyence Biomedical. MarketBeat recorded 2 mentions for Greenland Mines Ltd. Common Stock and 1 mentions for Psyence Biomedical. Greenland Mines Ltd. Common Stock's average media sentiment score of 1.14 beat Psyence Biomedical's score of 0.00 indicating that Greenland Mines Ltd. Common Stock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Psyence Biomedical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Greenland Mines Ltd. Common Stock	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Greenland Mines Ltd. Common Stock is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Psyence Biomedical	N/A	N/A	-$6.94M	$25.34	0.13
Greenland Mines Ltd. Common Stock	N/A	N/A	-$10.55M	-$0.32	N/A

Psyence Biomedical's return on equity of 0.00% beat Greenland Mines Ltd. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
Greenland Mines Ltd. Common Stock	N/A	-109.40%	-98.80%

Summary

Psyence Biomedical beats Greenland Mines Ltd. Common Stock on 6 of the 10 factors compared between the two stocks.

How does Psyence Biomedical compare to Actuate Therapeutics?

Actuate Therapeutics (NASDAQ:ACTU) and Psyence Biomedical (NASDAQ:PBM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

77.4% of Psyence Biomedical shares are held by institutional investors. 58.0% of Actuate Therapeutics shares are held by company insiders. Comparatively, 3.6% of Psyence Biomedical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Actuate Therapeutics has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, Psyence Biomedical has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market.

Actuate Therapeutics presently has a consensus price target of $13.67, suggesting a potential upside of 1,097.78%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Actuate Therapeutics is more favorable than Psyence Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Psyence Biomedical's return on equity of 0.00% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-430.93%	-180.86%
Psyence Biomedical	N/A	N/A	N/A

Actuate Therapeutics is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A
Psyence Biomedical	N/A	N/A	-$6.94M	$25.34	0.13

In the previous week, Actuate Therapeutics had 1 more articles in the media than Psyence Biomedical. MarketBeat recorded 2 mentions for Actuate Therapeutics and 1 mentions for Psyence Biomedical. Actuate Therapeutics' average media sentiment score of 0.50 beat Psyence Biomedical's score of 0.00 indicating that Actuate Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Actuate Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Psyence Biomedical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Psyence Biomedical beats Actuate Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Psyence Biomedical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PBM vs. The Competition

Export

Metric	Psyence Biomedical	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.35M	$11.51B	$6.84B	$12.77B
Dividend Yield	N/A	2.73%	2.60%	10.01%
P/E Ratio	0.13	791.62	279.15	25.53
Price / Sales	N/A	735.80	590.96	92.31
Price / Cash	N/A	71.54	72.11	49.39
Price / Book	0.43	10.85	13.02	6.11
Net Income	-$6.94M	$2.81B	$3.48B	$347.58M
7 Day Performance	7.52%	2.73%	3.40%	4.91%
1 Month Performance	5.39%	-3.09%	-2.80%	-2.06%
1 Year Performance	-89.64%	191.01%	73.17%	21.03%

Psyence Biomedical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PBM Psyence Biomedical	1.2461 of 5 stars	$3.28 +4.1%	N/A	-88.8%	$7.52M	N/A	0.13	N/A	Gap Up
ABVC ABVC BioPharma	0.2288 of 5 stars	$1.08 +6.9%	N/A	-66.6%	$26.82M	$510K	N/A	30	Gap Up
ALGS Aligos Therapeutics	3.3935 of 5 stars	$4.36 +2.5%	$38.50 +784.0%	-40.6%	$26.30M	$2.19M	N/A	90	Upcoming Earnings
ATNM Actinium Pharmaceuticals	1.7244 of 5 stars	$0.84 +0.0%	$5.00 +497.4%	-51.2%	$26.26M	$90K	N/A	30
GRML Greenland Mines Ltd. Common Stock	1.0779 of 5 stars	$0.20 +3.2%	N/A	-80.6%	$26.25M	N/A	N/A	5	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PBM) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Psyence Biomedical (PBM) Competitors

PBM vs. ABVC, ALGS, ATNM, GRML, and ACTU

How does Psyence Biomedical compare to ABVC BioPharma?

Summary

How does Psyence Biomedical compare to Aligos Therapeutics?

Summary

How does Psyence Biomedical compare to Actinium Pharmaceuticals?

Summary

How does Psyence Biomedical compare to Greenland Mines Ltd. Common Stock?

Summary

How does Psyence Biomedical compare to Actuate Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBM vs. The Competition

Psyence Biomedical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Psyence Biomedical (PBM) Competitors

PBM vs. ABVC, ALGS, ATNM, GRML, and ACTU

How does Psyence Biomedical compare to ABVC BioPharma?

Is ABVC or PBM more profitable?

Do insiders & institutionals have more ownership in ABVC or PBM?

Which has preferable earnings & valuation, ABVC or PBM?

Which has more volatility and risk, ABVC or PBM?

Do analysts rate ABVC or PBM?

Does the media refer more to ABVC or PBM?

Summary

How does Psyence Biomedical compare to Aligos Therapeutics?

Which has higher earnings & valuation, PBM or ALGS?

Is PBM or ALGS more profitable?

Do analysts prefer PBM or ALGS?

Which has more risk and volatility, PBM or ALGS?

Do insiders & institutionals believe in PBM or ALGS?

Does the media favor PBM or ALGS?

Summary

How does Psyence Biomedical compare to Actinium Pharmaceuticals?

Which has preferable valuation & earnings, PBM or ATNM?

Does the media refer more to PBM or ATNM?

Which has more volatility and risk, PBM or ATNM?

Do analysts prefer PBM or ATNM?

Do insiders & institutionals have more ownership in PBM or ATNM?

Is PBM or ATNM more profitable?

Summary

How does Psyence Biomedical compare to Greenland Mines Ltd. Common Stock?

Which has more risk & volatility, PBM or GRML?

Do analysts prefer PBM or GRML?

Do institutionals & insiders hold more shares of PBM or GRML?

Does the media refer more to PBM or GRML?

Which has better earnings & valuation, PBM or GRML?

Is PBM or GRML more profitable?

Summary

How does Psyence Biomedical compare to Actuate Therapeutics?

Do institutionals & insiders hold more shares of ACTU or PBM?

Which has more risk and volatility, ACTU or PBM?

Do analysts recommend ACTU or PBM?

Is ACTU or PBM more profitable?

Which has stronger valuation and earnings, ACTU or PBM?

Does the media refer more to ACTU or PBM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBM vs. The Competition

Psyence Biomedical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools